ACM
DNLI icon

ADAR1 Capital Management’s Denali Therapeutics DNLI Stock Holding History

ADAR1 Capital Management’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$35.9M Buy
1,871,455
+1,819,339
+3,491% +$36.2M 2.12% 10
2025
Q4 		$860K Buy
52,116
+600
+1% +$10.1K 0.06% 142
2025
Q3 		$748K Buy
51,516
+15,800
+44% +$227K 0.07% 114
2025
Q2 		$500K Buy
35,716
+21,843
+157% +$307K 0.08% 119
2025
Q1 		$189K Sell
13,873
-30,953
-69% -$593K 0.04% 149
2024
Q4 		$914K Sell
44,826
-57,000
-56% -$1.46M 0.18% 86
2024
Q3 		$2.97M Buy
101,826
+63,826
+168% +$1.58M 0.48% 39
2024
Q2 		$882K Buy
38,000
+36,000
+1,800% +$691K 0.17% 71
2024
Q1 		$41K Buy
+2,000
New +$37.6K 0.01% 191

Other funds holding DNLI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

ADAR1 Capital Management's DNLI Position: Q1 2026 in Review

ADAR1 Capital Management increased its Denali Therapeutics (DNLI) stake by 3,491% in Q1 2026, buying an estimated $36.2M and bringing the position to 1,871,455 shares worth $35.9M. The position accounts for 2.12% of the portfolio, ranked #10.

ADAR1 Capital Management first reported a position in DNLI in Q1 2024 and has held it in 9 quarters since. 268 funds tracked by Wall St. Rank hold DNLI as of Q1 2026.

  • ADAR1 Capital Management held 1,871,455 shares of Denali Therapeutics worth $35.9M as of Q1 2026.
  • ADAR1 Capital Management bought 1,819,339 Denali Therapeutics shares in Q1 2026, an estimated $36.2M.
  • Denali Therapeutics made up 2.12% of ADAR1 Capital Management's portfolio in Q1 2026, its #10 holding.
  • ADAR1 Capital Management first reported a position in Denali Therapeutics in Q1 2024 and has held it in 9 quarters since.
  • 268 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2026.

Based on ADAR1 Capital Management's 13F filing for Q1 2026, filed 18 May 2026.